Innovative CathWorks FFRangio Method Shows Promise in Cardiovascular Disease Management

Landmark Findings from the ALL-RISE Trial Presented at ACC.26

At the American College of Cardiology's Annual Scientific Session (ACC.26) held in New Orleans, Louisiana, groundbreaking results from the ALL-RISE Trial were shared by Dr. Ajay J. Kirtane from New York-Presbyterian/Columbia University Irving Medical Center. The study focused on assessing the efficacy of CathWorks’ unique FFRangio system in comparison to conventional invasive pressure wire techniques. Simultaneously, results were published in the esteemed New England Journal of Medicine, marking a significant milestone in cardiovascular technology.

Key Trial Insights

The ALL-RISE Trial involved a substantial cohort of 1,930 patients selected from 59 medical institutions across North America, Asia, Europe, and the Middle East. Patients diagnosed with coronary stenoses of intermediate severity were randomly divided into two groups. One group received physiological assessments using the innovative CathWorks FFRangio system (comprising 965 patients), while the other group underwent assessments via traditional wire-based methods (also consisting of 965 patients).

This trial stands out as the first randomized controlled study in the U.S. that evaluates an FDA-approved angiography-derived physiology solution for lesion assessment, as well as the first to juxtapose this technology against invasive pressure wire approaches.

Comparative Outcomes

The primary outcome measured was the occurrence of major adverse cardiac events (MACE) within one year. Impressively, the results revealed an event rate of 6.9% for the FFRangio group, compared to 7.1% for the pressure wire group, evidencing non-inferiority (HR 0.98; 95% CI 0.70 to 1.39) with a remarkable non-inferiority p-value of 0.0008. Both groups showcased comparable safety profiles, demonstrating no significant differences in terms of bleeding incidents, acute kidney injury, or other procedure-related complications.

In terms of operational efficiency, the FFRangio group notably exhibited better resource utilization in catheterization labs, indicated by reduced radiation exposure and a lesser need for contrast mediums than their pressure wire counterparts. Although the FFRangio group recorded a slightly higher number of coronary interventions, it notably achieved a faster process for physiology analysis and an overall shorter procedure duration.

Expert Opinions

In a collective statement, key figures such as Dr. Martin B. Leon, the Executive Study Chair, and Dr. Kirtane, emphasized that significant advancements in cardiovascular healthcare stem from collaborative efforts and clinical determination to surpass established practices. They highlighted the potential of the ALL-RISE Trial results, emphasizing that the CathWorks FFRangio system—utilizing artificial intelligence and advanced computation—could redefine traditional methodologies for assessment.

Technological Edge

The CathWorks FFRangio System provides a transformative approach by leveraging standard angiographic images to derive physiological measurements, eliminating the necessity for invasive procedures and drug stimulation. This system’s ability to deliver comprehensive physiological assessments throughout the coronary tree enhances the treatment decision-making process in cases of multi-vessel disease. Furthermore, its unique features like the virtual pullback curve and Lesion Impact tool grant medical professionals insights into residual ischemia, offering individualized strategies for their patients.

According to Ramin Mousavi, President and CEO of CathWorks, the results underscore the relevance of the ALL-RISE Trial findings in suggesting that CathWorks FFRangio could establish itself as a pioneering standard in coronary physiology assessments. The study's positive outcomes contribute to a wealth of evidence accumulated from diverse patient populations treated using FFRangio guidance, fortifying its advantages over traditional invasive techniques.

Jason Weidman from Medtronic expressed enthusiasm over the global acceptance of the CathWorks FFRangio solution, noting its groundbreaking capabilities in contemporary catheter labs, subsequently influencing coronary artery disease diagnoses and treatments positively.

Conclusion and Future Directions

The ALL-RISE Trial not only reinforces the clinical efficacy of CathWorks FFRangio as a reliable alternative to wire-based assessments but also highlights its operational advantages, serving as a vital component in the evolving landscape of cardiovascular healthcare. The hope is that with corroborated data and technological advancements, FFRangio will catalyze a shift towards modernized practices in cardiac care.

To dive deeper into the scientific findings, the full study is accessible via the New England Journal of Medicine here.